Radiopharmceutical Indications Should Not Be Disease Specific, CORAR Says
Executive Summary
Radiopharmaceutical indications should not be disease specific, unless a sponsor is seeking such an indication Council on Radionuclides and Radiopharmaceuticals Secretary Robert Morgan (DuPont Merck) maintained at a Feb. 27 FDA public meeting on developing regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring.